The aim of the study was to examine insulin homeostasis during growth hormone (GH) therapy, and to investigate the effect of GH treatment on insulin and leptin concentration in obese children. SUBJECTS: Nineteen obese children (8 with Prader-Willi Syndrome (PWS)) were treated with GH 0.1 IUakgaday dose for 3 months and were compared with 29 non-treated age and sex matched obese children (9 PWS) and 49 GH treated non-obese short children. Mean age of the children was 10.3 AE 1.8 (6.7 ± 13.8) y, with body mass index of 23.6 AE 10.4 (11.5 ± 47) kgam 2 . RESULTS: Leptin concentration decreased and was correlated inversely with initial leptin value (r 2 À0.374, P`0.001) and decreased body mass (r 2 0.338, P 0.001). Insulin sensitivity index was not signi®cantly changed during therapy. Leptin decrease after 3 months of GH administration was correlated inversely with the increase in ®rst phase insulin response to intravenous glucose tolerance test (IVGTT) (r 2 À0.595, P`0.001). Results of long-term follow-up of treated patients demonstrated a decrease in insulin concentration after cessation of therapy. In GH-treated subjects, the glucose increase in response to glucose load appeared to be higher than in untreated subjects. CONCLUSION: The high insulin response to glucose load seen in GH-treated subjects was appropriate to their glucose concentration and the insulin sensitivity index was unchanged relative to the pretreatment period. Increased insulin dosage in our patients did not induce an increase in leptin concentrations as had been hypothesised.
Introduction
Recent ®ndings indicate a strong genetic basis for human obesity. It has been postulated, in mice, that fat storage induces a signal to the brain which, in turn, reduces appetite and increases energy expenditure. 1, 2 Such signaling is attributed to the adipocyte derived ob gene product, leptin. 3, 4 However, in humans, serum leptin concentrations have been reported to decrease during weight loss. 5 Leptin is correlated with body mass index (BMI) 6 and with more speci®c estimates of body fat. 5, 6 Growth hormone (GH) therapy may cause a reduction in body fat mass (BFM), 7 but together with lipolysis, as seen in GH-treated adults and children, 8 ± 10 it may induce depressed glucose utilisation. 11 and consequent insulin resistance. Nevertheless, insulin was reported to increase leptin mRNA in adypocytes. 12 The purpose of this study was to investigate the interrelationship between GH, insulin and leptin in non-GHde®cient children with a wide range of BFMs and the effect of GH therapy on glucose tolerance.
Patients and methods
Nineteen markedly obese patients, 8 with Prader Willi Syndrome (PWS), who had continued to gain weight despite weight-reduction programs, were treated with GH. An additional group of 29 age-matched obese patients (9 PWS) were evaluated in the basal state. PWS is characterised, among other features, by early childhood obesity with uncontrollable appetite, mental de®ciency, hypogonadism and short stature. 13 The obese patients were compared to 49 GHtreated, age and sex-matched, normal short children (NSC). This open label, prospective study was designed to evaluate the effect of GH therapy on weight gain and fat mass in obese children in an effort to halt their weight gain. In all PWS patients, the diagnosis was con®rmed by demonstration of a chromosome 15 defect. All children were prepubertal, not on medication and free of chronic disease. A detailed medical history and a complete physical examination was performed in all patients. Laboratory work-up included a complete blood count, ESR, liver and kidney function tests and anti-endomesial antibodies in the short children. A detailed analysis of all patients' 3 day food intake record was performed before initiation of the study and at 3 monthly intervals. Energy intake was reported as %RDA requirement. The mean age of the participants was 10.3 AE 1.8 y (6.7 ± 13.8) with a BMI of 23.6 AE 10.4 (11.5 ± 47) kgam 2 . Forty percent of each group were females. Height (SDS), weight (SDS) (Tanner), and BMI (SDS) of the participants are presented in Table 1 . GH status was evaluated by a 24 h continuous blood sampling for a determination of the integrated concentration of GH (ICGH). Provocation tests (clonidine and arginine) were performed as previously described. 14, 15 Bone age was determined from ®lms of the left hand, according to Greulich and Pyle. After initial evaluation, the patients were treated daily with 0.1 IUakg GH (Bio-Tropin, Bio-Technology General, Israel) for 3 months. GH therapy was continued for 1 y in ten obese patients (four PWS) and in all NSC.
Before initiation of treatment, at 3 months and at 1 y of GH therapy, BFM, fasting blood concentration of leptin, insulin (during VGTT; 0.3 gakg BW), insulin growth factor 1 (IGF-1) glucose and haemoglobin A 1C were monitored. Blood samples during the IVGTT were taken at 1, 3, 5, 10, 20, 30, 40, 50, 60, 90, 120, 150, and 180 min. GH binding protein (GHBP) was determined before initiation of GH therapy and at 3 months of treatment. The Ethical Committee approved the protocol, which conformed with the Declaration of Helsinki, and informed consent was obtained for each subject.
Height was measured on a Harpenden stadiometer; subjects were clad in light clothing during weight measurement. BFM was determined by bioelectric impedance (BIA-apparatus, RJL Sys, Detroit USA) using the equation described by Azcue et al. 16 Hormone Concentrations were determined with commercial RIA kits. The IGF-I kit utilises acid to separate IGF-I from its binding proteins on minicolumns. Leptin was determined with an RIA kit (Linco Research Inc., St. Charles, MO, USA), at an assay sensitivity of 0.5 ngaml. GH was determined using a double-antibody RIA kit (Sorin HGHK-2, Vercelli, Italy). GH-BP was measured by GH-binding assay based on dextran-coated charcoal separation. 17 Results of GH-BP are given as percentage of a normal adult control pool. Insulin sensitivity was calculated by the MINI-MOD program. 18 Statistical evaluation was performed by SPSS (Erkarth, Germany) using paired t-test, Mann ± Whitney Rank Sum (MWRS), regression univariate, multivariate and stepwise when appropriate.
Results
In this report, we evaluated the interrelation between insulin, leptin and growth hormone in 97 children exhibiting a normal growth rate. Forty-eight were obese and 49 were short, non-obese children. Although the maximal GH response of many of the obese children to GH provocative tests (GH-MAX) was`10 mcgal (as a group 10.9 AE 10.9 mcgal), their IGF-I was normal. Despite the low GH-MAX, their normal growth rate and IGF-I were not consistent with the diagnosis of GH de®ciency. No signi®-cant differences were noted in any of the parameters studied between the PWS and the other obese patients; hence we combined them for the purpose of analysis. In the short children, the normal growth rate and the normal GH response to stimulation (b10 mcgal, as a group 20.3 AE 9.9) Insulin, leptin and growth hormone in children Z Zadik et al excluded GH de®ciency. Even though normal growth rate and normal GH-MAX were seen in b50% of this group, IGF-I was in the`GH de®ciency range', possibly as a result of the low energy intake of these children. Indeed, IGF-I was strongly correlated with energy intake (r 2 0.682, P`0.001). There was a signi®cant association between maximal GH response to stimulation and ICGH and IGF-I (r 2 0.522 and 0.586, P`0.001, respectively). Both ICGH and GH-MAX negatively correlated with BMI-SDS and BFM (r 2 À0.622, r 2 À0.640, P`0.001 and r 2 À0.284, r 2 0.509, P`0.001, respectively; Table 3 ). As expected, a notable link was shown between energy intake and markers of adiposity. BFM, and BMI-SDS positively correlated with IGF-I and GHBP (r 2 0.767, r 2 0.453, P`0.001 and r 2 0.624, r 2 0.368, P`0.001, respectively. The correlation matrix between leptin, insulin and GH axis variables of all children, prior to the start of GH therapy, is presented in Table 2 . BMI-SDS and BFM corresponded with leptin, insulin sensitivity index and ®rst phase insulin response to IVGTT. The model most appropriate to interact with log leptin was identi®ed by stepwise regression analysis. ICGH and BMI-SDS or BFM were the best predictors of log leptin, r 2 0.82, P`0.001 or r 2 0.912, P`0.001, respectively. First phase insulin response to IVGTT highly correlated with IGF-I log leptin, r 2 0.599, P`0.001. As expected, during the ®rst 3 months of administration, the GH treatment elicited a signi®cant increase in IGF-I, 35.3 AE 15.5 and 21.3 AE 14.5 nmolal greater in obese patients than in the NSC, respectively (P`0.003), with a more moderate effect thereafter (Table  2) . GHBP levels declined during the ®rst 3 months of GH therapy in 10 of the obese children.
No signi®cant changes in body weight were noted during the ®rst 3 months of the study in either group. BFM decreased signi®cantly in the obese group: 6.6% AE 4.2 compared to 1.6 AE 1.6 in the NSC group, with no further decrease at one year. Leptin concentration decreased substantially during the ®rst 3 months of GH therapy in the obese and non-obese subjects (À37 AE 28, P`0.001 and À1.6 AE 0.1, P`0.05, respectively with no signi®cant effect thereafter. Leptin concentration rose to 38 AE 7.1 at 12 months of the study in obese patients who discontinued therapy. When leptin and BFM were to transformed, leptin decrease was inversely correlated with initial leptin value (r 2 À0.374, P`0.001) and with body mass decrease (r 2 0.338, P 0.001). After 3 months of GH administration, leptin decrease contrasted with the increase in ®rst phase insulin response to IVGTT (r 2 À0.595, P`0.001). Insulin concentrations prior to GH administration were higher in the obese than in the NSC group. After 3 months of GH therapy, insulin concentrations increased as demonstrated by the ®rst phase insulin response (1 3 minutes) to IVGTT (FPI) by 92.6 AE 80.7 and 3.6 AE 2.1 mual in the obese and non-obese patients P`0.001 (Table 2 ) with no major change thereafter. At the same time, no change in insulin sensitivity index was induced in the two groups by 3 months of GH therapy (0.007 AE 0.34 and 3.5 AE 2.1 in the obese and NSC children) ( Table 2) . IGF-I values increased during GH therapy in both the obese and non-obese children (always higher in the obese children) ( Table 2 ). Leptin concentrations were in accordance with weight-SDS, BMI-SDS and BFM before initia- Insulin, leptin and growth hormone in children Z Zadik et al tion of GH therapy (r 2 0.716, P`0.001, r 2 0.736, P`0.001 and r 2 0.767, P`0.001, respectively). Log basal leptin and initial BFM (r 2 0.634, P`0.001) were determined by stepwise regression analysis to present the best combination for predicting BFM decrease during GH therapy. Leptin was also correlated with basal insulin concentration (r 2 0.653, P`0.001) and with IGF-I (r 2 0.611, P`0.001). Insulin values positively corresponded with IGF-I both before initiation and at 3 months of GH therapy (r 2 0.578, P`0.001 and r 2 0.608, P`0.001, respectively). During treatment, one of the PWS patients, exhibiting antiinsulin and anti-islet cell antibodies developed diabetic ketoacidosis, symptoms that were alleviated upon cessation of GH therapy. Hemoglobin A 1C values were normal throughout the study at all times except for a transitory increase in the above-mentioned patient.
Discussion
GH administration resulted in a reduction of BFM and a decrease in plasma leptin concentrations after 3 months of GH therapy in obese children with no change thereafter. Prior to this therapy, the obese patients experienced uncontrolled appetites and constant weight gains. Our study concurs with previous short-term reports on adults and children including PWS in which the lipolytic effect of GH on body composition appeared to induce reduction in body fat. 7 ± 10,19,20 In those studies, leptin and its relation to glucose homeostasis were not determined. Leptin concentrations are modulated by weight gain 21 and loss 6 in adult humans. The ®nding of increased leptin in obese adults and children. 6, 21 led to the hypothesis of resistance to leptin activity at the level of the hypothalamus, 13, 22 resulting in increased appetite and decreased energy expenditure despite adequate leptin production in the adipocytes. In children, no age effect has been found, but a decline in log leptin occurs as puberty progresses. 22 Hassink et al 22 hypothesised that children manifest a relative`leptin resistance' to support the increased growth and development of reproductive capacity. Whereas higher leptin concentrations in children during periods of accelerated growth could be anticipated, they were not seen in the NSC group; following GH treatment for one year, no signi®cant changes were seen in leptin concentrations. Although growth velocity was as expected for a pubertal growth spurt in the NSC group, the patients remained prepubertal. The explanation put forward by Hassink et al 22 could apply also to normally growing and maturing children.
Insulin resistance and increased insulin concentrations have been associated with human obesity. 23 Insulin has been shown to increase leptin mRNA in adipocytes, thus suggesting that insulin stimulates leptin secretion. 24 ± 26 Direct regulation of leptin by insulin has also been proposed. 24 ± 26 In our study, higher insulin values were found in obese children during GH therapy both in the basal state and during IVGTT. Despite these increments in insulin, leptin concentrations did not increase; on the contrary, a signi®cant decrease in leptin was observed. Moreover, in all our patients, as a group, the increase in fasting insulin concentrations during GH administration correlated with the reduced leptin values. Similar results were noted in GH-de®cient adults on GH replacement therapy. 15 One can suggest that the negative correlation between insulin and leptin simply implies that leptin re¯ects the amount of body fat and not insulin secretion. In any event, the relationship between IGF-I, insulin and leptin remains unclear. Cohen et al 27 have suggested that leptin secretion is one way in which obesity causes insulin resistance. Again, in our model, insulin increased during GH therapy while leptin decreased; however we studied this relationship during treatment with superphysiological amounts of GH. Nevertheless, it is possible, as suggested by Schwartz et al 28 that plasma leptin and insulin are associated with body adiposity via different mechanisms. An additional possibility is an effect of insulin on leptin via IGF-I. Insulin has been shown to enhance the bioavailability of IGF-I; it increases plasma IGF-I without affecting plasma IGF-BP3 concentration. 29 The unbound form of IGF-I could be a regulatory factor of plasma leptin, independent of IGF-I's effect on body fat. 30 GHBP is identical in structure to the extracellular domain of the GH receptor. 31, 32 Low GHBP has been detected in anorexia nervosa and high GHBP is seen in obesity, 33 ,34 a phenomena also seen in our obese patients whose GHBP concentrations decreased with the decrease in BFM. In NSC where the effect of GH on BFM was minor, an increase in GHBP was noted. We reported previously that GH therapy can induce an increase in GHBP; 35 according to our results, BFM appears to be a stronger determinant of GHBP than GH therapy.
